AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06170008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline gauze
Description: Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
Study NCT05300308 — intervention group
Intervention type: OTHER
Intervention: usual care
Description: The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
Study NCT06010303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: LBL-007 will be administered at a standard dose intravenously.
Study NCT06010303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered at a standard dose intravenously.
Study NCT06010303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab will be administered at a standard dose intravenously.
Study NCT06010303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Doublet
Description: Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study NCT06010303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Doublet
Description: Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Mouth Rinse
Description: A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
Study NCT05306340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Mouth Rinse
Description: A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
Study NCT06218420 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
Study NCT05398250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention tailored for Autistic Individuals
Description: To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
Study NCT05398250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts
Description: SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation
Study NCT06776744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).
Study NCT06772519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: green colored lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
Study NCT06772519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue colored lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
Study NCT06772519 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: colorless (transparent) lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
Study NCT06777160 — intervention group
Intervention type: PROCEDURE
Intervention: Collecting data from patients who underwent arthroplasty and cement was used
Description: Collecting data that may change in cement reaction before, during and after surgery from patients who underwent arthroplasty and cement use and taught it to artificial intelligence.
Study NCT06776120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal chemical test (FIT)
Description: Eligible participants will be instructed to collect their two stool samples within seven days prior to undergoing bowel preparation. These stool samples will be then submitted for a quantitative FIT (OC-SENSOR, EIKEN CHEMICAL, Japan). Colonoscopic observations and histopathological findings will be employed as the definitive reference standards for diagnosis.
Study NCT06777394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: The HIIT program begins with a warm-up, followed by high-intensity repetitions separated by moderate-intensity recovery intervals. High-intensity exercises are performed near maximum effort, while moderate-intensity periods are maintained at 50% effort. HIIT exercises, involving low-skill movements in short bursts, enhance blood sugar regulation and fat-burning capacity.~The HIIT protocol has four phases:~Warm-Up: 10 minutes, gradually increasing to about 60% of maximum heart rate. Intervals: 4 minutes at 85-95% maximum heart rate. Relief/Recovery: 3 minutes at 60% maximum heart rate, repeated four times. Cool Down: 5 minutes, bringing the heart rate down to around 50% of maximum. Three key components determine the success of HIIT: intensity, duration, and recovery period. Exercises include dumbbell and kettlebell exercises, push-ups, squats, jump training, and stationary cycling
Study NCT06777394 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatmet
Description: outine physical therapy includes stretching exercises, exercises to maintain a normal range of motion, and low-intensity and aerobic exercises for the patients.~Low-Intensity Exercise: The effects of low-intensity exercise become noticeable after about 20 minutes, providing a metabolic boost during the activity. Generally, a longer exercise duration further enhances metabolism.
Study NCT04512560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training
Description: General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
Study NCT04512560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Training using Conventional Training Program
Description: General surgery residents (PGY 1-5) will continue their usual residency training.
Study NCT06363201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin Oral solution
Description: Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
Study NCT06433349 — intervention group
Intervention type: OTHER
Intervention: Survey and interviews
Description: Questionnaires and interviews
Study NCT04816188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy and Activity Modification
Description: Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
Study NCT05182398 — intervention group
Intervention type: OTHER
Intervention: Assesment
Description: Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
Study NCT05935917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Description: 100 mg tablet of Form H and 100 mg tablet of Form II
Study NCT06160999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Religious conferences
Description: The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
Study NCT06160999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine-in-a-van
Description: For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
Study NCT06414889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim or biosimilar)
Description: Given by IV or SC
Study NCT06414889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Given by procedure
Study NCT06414889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given by IV
Study NCT06169254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial current stimulation (tCS)
Description: Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
Study NCT06169254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial current stimulation (tCS)
Description: Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
Study NCT04879264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-rating scale for severity of sleep disorders
Description: Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
Study NCT04879264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-rating scale for distress caused by sleep disorders
Description: Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
Study NCT06186648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab + Obinutuzumab
Description: Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
Study NCT05383248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Reward - High Variance
Description: Computerized reward learning task designed to increase reward responsiveness
Study NCT05383248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Reward - Low Variance
Description: Computerized reward learning task designed to have minimal effect on reward responsiveness
Study NCT05935345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addressing NSSI in schools
Description: During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
Study NCT05935345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
Study NCT06444880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Given by IV
Study NCT06444880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV
Study NCT05167734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Dextran
Description: 1000 mg IV
Study NCT05167734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Description: 40,000 units subcutaneous
Study NCT06465225 — intervention group
Intervention type: DEVICE
Intervention: Use of a powered alternating pressure air mattress
Description: Patients with a medium to high risk of developing pressure injury, without pressure injury, up during the day and lying between 15 and 20 hours per day will ly a on a R'GO Soins overlay mattress
Study NCT06647030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.DTx sessions
Description: Participants will interact with CURATE.DTx twelve minutes per day, three days a week, for ten weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force.
Study NCT06647030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use thematic analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
Study NCT04899141 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: stenting with the ihtDEStiny® sirolimus eluting stent
Study NCT05567757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arteriovenous conduit implant
Description: Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
Study NCT06252194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and doxycycline
Description: Metformin 500 mg tablet twice daily
Study NCT06252194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and doxycycline
Description: Metformin 500 mg tablet twice daily
Study NCT05456828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG712
Description: ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Study NCT06272851 — intervention group
Intervention type: DEVICE
Intervention: optical coherence tomography
Description: measuring choroidal thickness using optical coherence tomography
Study NCT06401200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bar retained implant overdenture
Description: use of bar attachment in completely edentulous patient
Study NCT06401200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bar retained implant overdenture
Description: use of bar attachment in completely edentulous patient